Interim guidance. 12 May 2021. The Continuity of essential health services: Facility Assessment Tool can be used by countries to rapidly assess the capacity of health facilities to maintain the provision of essential health services during the COVID-19 pandemic. It can help to alert the authorities ...and other stakeholders about where service delivery and utilization may require modification and/or investment. This assessment tool covers the following aspects of essential health services:
health workforce (numbers, absences, COVID-19 infections, health workforce management, training and support);
financial management and barriers;
service delivery and utilization (facility closures, changes in service delivery, community communication campaigns, changes in service utilization and catch-up strategies);
IPC capacities (protocols, safety measures, guidelines and the availability of personal protective equipment (PPE) for staff);
availability of therapeutics, diagnostics and supplies, and vaccine readiness; and
provision of COVID-19 primary care services.
more
This global guidance provided the framework for over 100 countries to develop their NDVPs. This updated (second) version supersedes the previous version published in 16 November 2020. New information has been added on the following areas:
the COVID-19 Partners Platform;
the use of COVID...-19 simulation exercises to test deployment strategies;
the indemnity agreement and no-fault compensation programme for vaccines secured through the COVAX Facility in the Advance Market Commitment (AMC) eligible economies;
the availability and use of the WHO-UNICEF COVID-19 Vaccine Introduction and deployment Costing (CVIC) tool;
the COVAX Facility’s humanitarian buffer that enables allocation of vaccine to cover high-risk populations in humanitarian settings;
recommendations for vaccination of pregnant and lactating women;
supplementary information on infection prevention and control (IPC) measures to be used to deliver COVID-19 vaccines safely;
the WHO licensed COVID-19 vaccines product-specific information;
use of geospatial data and digital micro plans for equitable access and delivery of COVID-19 vaccines;
lessons learned from the development of NDVPs and early experiences in COVID-19 vaccine deployment in countries; and
updated additional resources at the end of each chapter.
more
Member States have requested WHO policy guidance on how to facilitate the implementation of national AMS activities in an integrated and programmatic approach. This policy guidance responds to that demand from Member States and is anchored in public health guiding principles in the human health sect...or. It aims to provide a set of evidence-based and pragmatic recommendations to drive comprehensive and integrated AMS activities under the purview of a central national coordination unit, National AMR steering or coordinating committees or other equivalent national authorities.
Available in English, French, Spanish, Russian, Arabic, Chinese
more
COVID-19 Vaccines: 1 Safety Surveillance 2 Manual
While there is no indication that pregnant women have an increased susceptibility to infection with SARS-CoV-2, there is evidence that pregnancy may increase the risk of severe illness and mortality from COVID-19 disease in comparison with non-pregn...ant women of reproductive age. As seen with non-pregnant women, a high proportion of pregnant women have asymptomatic SARS-CoV-2 infection and severe disease is associated with recognized medical (e.g., high body-mass index (BMI), diabetes, pre-existing pulmonary or cardiac conditions) and social (e.g., social deprivation, ethnicity) risk factors. Pregnant women with symptomatic COVID-19 appear to have an increased risk of intensive care unit admission, mechanical ventilation and death in comparison with non-pregnant women of reproductive age, although the absolute risks remain low. COVID-19 may increase the risk of preterm birth, compared with pregnant women without COVID-19, although the evidence is inconclusive.
more
To provide supply & equipment to collect, test and transfuse 50 blood bags.
The new Collection testing and transfusion kit 2021 is specially designed for emergency settings where blood transfusion is crucial. It contains all the necessary supply & equipment needed to collect blood, test it agains...t HIV, Malaria, Hep B and C, and syphilis, make sure of the blood grouping, and ensure transfusion.
The equipment such as blood bags, IV transfusion set and vacutainer blood collection tubes are from BD or Fresenius Kabi, also available as single item in the WHO catalogue.
more
2nd. edition
The new edition has been developed to make widely available to programme managers, health care workers in endemic settings, academic researchers, and other key partners, a concise source of information on strategies for MMDP for LF. It is a product of efforts to elaborate and concepts ...and approaches introduced in the previous edition, with a focus on ensuring that countries have the tools necessary to provide the essential package of care for LF.
more
23 December 2020 This document summarizes WHO recommendations for the rational use of personal protective equipment (PPE) in health care settings and temporary strategies during acute supply shortages. This document also contains 2 Annex sections describing updated PPE use recommendations for health... workers based on the transmission scenario, setting, and activity in the context of COVID-19 (Annex 1), and updated considerations for the decontamination or reprocessing of PPE (Annex 2). This guidance is intended for public health authorities, organizations, and focal persons involved in decisions regarding PPE distribution, management, and use by health workers.
Available in Arabic, French, English, Spanish and Russian
more
Every year, an estimated 15 million babies are born preterm – before 37 weeks of pregnancy. That is more than 1 in 10 live births. Approximately 1 million children die each year worldwide due to complications from their early birth. Those that survive often face a lifetime of ill-health including ...disability, learning difficulties, and visual and hearing problems.
Half of the babies born at or below 32 weeks (2 months early) die in low-income settings, due to a lack of feasible, cost-effective care, such as warmth, breastfeeding support, and basic care for infections and breathing difficulties. In high-income countries, almost all these babies survive.
more
The report finds that, as of 3 November, in 87 countries with age-disaggregated data, children and adolescents under 20 years of age accounted for 1 in 9 of COVID-19 infections, or 11 per cent of the 25.7 million infections reported by these countries. More reliable, age-disaggregated data on infect...ion, deaths and testing is needed to better understand how the crisis impacts the most vulnerable children and guide the response
more
WHO published guidance for clinicians and health care decision-makers on the use of corticosteroids in patients with COVID-19.
We recommend systemic corticosteroids for the treatment of patients with severe and critical COVID-19. We suggest not to use corticosteroids in the treatment of patients ...with non-severe COVID-19 as the treatment brought no benefits, and could even prove harmful. Treatment should be under supervision of a clinician.
Corticosteroids are listed in the WHO model list of essential medicines, readily available globally at a low cost. WHO encourages countries to maintain sufficient stocks of corticosteroids to treat COVID-19 and the other disease for which they are effective, while not maintaining excessive stocks which could deny other countries access.
more
For COVID-19, as for many infectious diseases, the true level of transmission is frequently underestimated because a substantial proportion of people with the infection are undetected either because they are asymptomatic or have only mild symptoms and thus typically fail to present at healthcare fac...ilities. There may also be neglected or under-served segments of the population who are less likely to access healthcare or testing. Under-detection of cases may be exacerbated during an epidemic, when testing capacity may be limited and restricted to people with severe cases and priority risk groups (such as frontline healthcare workers, elderly people and people with comorbidities). Cases may also be misdiagnosed and attributed to other diseases with similar clinical presentation, such as influenza.
Differences in mortality between groups of people and countries are important proxy indicators of relative risk of death that guide policy decisions regarding scarce medical resource allocation during the ongoing COVID-19 pandemic. This document is intended to help countries estimate CFR and, if possible, IFR, as appropriately and accurately as possible, while accounting for possible biases in their estimation
more
This guidance provides considerations and a series of options that can be used to inform country strategies in managing any shortages of personal protective equipment.Re-use and reprocessing of single-use PPE must be a last resort temporary measure to be adopted until stocks are replenished. The WH...O and other agencies are currently conducting research about this and further guidance will likely become available soon.
more
Handbook of COVID-19 Prevention and Treatment, expecting to share their invaluable practical advice and references with medical staff around the world. This handbook compared and analyzed the experience of other experts in China, and provides good reference to key departments such as hospital infect...ion management, nursing, and outpatient clinics. This handbook provides comprehensive guidelines and best practices by China's top experts for coping with COVID-19.
This handbook, provided by the First Affiliated Hospital of Zhejiang University, describes how organizations can minimize the cost while maximizing the effect of measures to manage and control the coronavirus outbreak. The handbook also discusses why hospitals and other healthcare institutions should have command centers when encountering a large-scale emergency in the context of COVID-19. This handbook also includes the following:
- Technical strategies for addressing issues during emergencies.
- Treatment methods to treat the critically ill.
- Efficient clinical decision-making support.
- Best practices for key departments like inflection management and outpatient clinics.
more
While many of the countries hit by the COVID-19 in the first few months of the year are now beginning to relax lockdown measures as infection and death rates fall, in the regions most affected by HIV, TB and malaria, such as Africa, South Asia and Latin America, the pandemic continues to accelerate.... In lower resource settings, lockdowns are less effective and hard to sustain, and clinical care facilities are extremely limited. In such environments, the response to COVID-19 must focus on containing the pandemic’s spread as far as possible through testing, contact tracing and isolation, protecting the health workforce through training and the provision of personal protective equipment (PPE) and minimizing the knock-on impact on other diseases through shoring up fragile health systems, and adapting existing disease programs.
more
Les coronavirus forment une vaste famille de virus qui peuvent être pathogènes chez l’homme et chez l’animal. On sait que, chez l’être humain, plusieurs coronavirus peuvent entraîner des infections respiratoires dont les manifestations vont du simple rhume à des maladies plus graves comme... le syndrome respiratoire du Moyen-Orient (MERS) et le syndrome respiratoire aigu sévère (SRAS).
more
Immunizations are an essential health service that protect susceptible individuals from vaccine-preventable diseases (VPD).2 By providing timely immunizations, individuals and communities remain protected and the likelihood of a VPD outbreak decreases
This publication is available in Arabic, Chines...e, English, French, Russian and Spanish
more
COVID-19 is a pandemic that is currently ravaging the world. Infection rate is steadily increasingin Sub-Saharan Africa. Pregnant women and their infants may suffer severe illnesses due to theirlower immunity. This guideline prepares and equips clinicians working in the maternal and new-born section...s in the sub-region to manage COVID-19 during pregnancy and childbir
more
Document d’information scientifique
24 avril 2020
Le développement d’une immunité face à un agent pathogène à la suite d’une infection naturelle comporte plusieurs étapes et prend généralement une à deux semaines. Une infection virale entraîne immédiatement une réponse immunit...aire innée, non spécifique, au cours de laquelle les macrophages, les neutrophiles et les cellules dendritiques ralentissent la progression du virus et peuvent même éviter l’apparition de symptômes. Cette réponse non spécifique est suivie d’une réponse adaptative, au cours de laquelle l’organisme produit des anticorps qui se lient spécifiquement au virus. Ces anticorps sont des protéines appelées immunoglobulines. L’organisme produit également des lymphocytes T qui reconnaissent et éliminent les cellules infectées par le virus. Cette réponse adaptative permet parfois d’éliminer le virus de l’organisme et, si elle est suffisamment forte, d’éviter l’aggravation de la maladie ou la réinfection par le même virus. Ce processus est souvent mesuré par la présence d’anticorps dans le sang.
more
Interim Guidance 7 March 2020
This document provides technical guidance for government authorities, health workers, and other key stakeholders to guide response to community spread. It will be updated as new information or technical guidance become available. For countries that are already preparin...g or responding, this document can also serve as a checklist to identify any remaining gaps.
more
Persons with acute respiratory illness with sudden onset of at least one of the following: cough, sore throat, shortness of breath or fever [≥ 38°C (measured) or history of fever (subjective)] irrespective of admission status AND In the 14 days prior to onset of symptoms, met at least one of the ...following epidemiological criteria: Were in close contact1 with a confirmed2 or probable3 case of SARS-CoV-2 infection; OR Had a history of travel to areas with presumed ongoing community transmission of SARS-CoV-2; (Visit WWW.NICD.AC.ZA for an updated case definition). OR Worked in, or attended a health care facility where patients with SARS-CoV-2 infections were being treated. OR Admitted with severe pneumonia of unknown aetiology.
more